SAP’s Dividend Hits Accounts, but Its Healthcare AI Bet Offers Fresher Hope

The €2.88 billion cheque has cleared. SAP shareholders who held through the ex-dividend date on 6 May are now seeing the cash land in their accounts — €2.50 per share, a 6.4% increase on last year’s payout. Yet the stock is taking none of the credit. The shares slipped another 1.8% on Friday to trade around €147, extending a year-to-date decline of 27% that has left the Walldorf-based software giant nursing a near-46% gap from its 52-week high of €271.60.

Technically, the picture is peculiar. The Relative Strength Index sits at 75.5, a reading that typically flags an overbought condition. For a stock trading so far below its moving averages, that kind of momentum indicator is unusual — and suggests the selling pressure may be exhausting itself rather than building.

Cloud Numbers Still Shine

Operationally, the narrative remains one of robust expansion. First-quarter cloud revenue climbed 27% to just under €6 billion, with the cloud ERP suite accelerating 30% in constant currency. The cloud order backlog swelled to €21.9 billion. Management is guiding for full-year 2026 cloud revenue between €25.8 billion and €26.2 billion, representing 23–25% growth at constant currencies — despite a slight miss on total revenue in the opening quarter.

The executive team has been candid about headwinds. A slowdown is expected in the second quarter, partly because one-off tailwinds that boosted Q1 will not repeat. Broader macroeconomic uncertainty is also giving some customers pause on investment decisions.

Should investors sell immediately? Or is it worth buying SAP?

A Healthcare Pivot Takes Shape

While the dividend story is backward-looking, a strategic move into healthcare offers a forward angle. SAP has partnered with Fresenius, the DAX-listed hospital operator, to invest in Avelios Medical — a developer of cloud-based hospital information systems. The plan is to replace SAP’s legacy IS-H system with an open, AI-native platform built on the SAP Business Technology Platform.

Avelios will use that foundation to embed AI assistants such as SAP Joule into materials management and workforce planning. The partnership was first telegraphed in January, when the companies announced plans to invest a three-digit million-euro sum in digital health solutions over the medium term, with a focus on European data sovereignty.

If the Avelios software rolls out smoothly across Fresenius’s clinics, the project could become a blueprint for the tightly regulated European healthcare market. For SAP, it offers a direct channel into a sector that reduces reliance on the core ERP business — and opens up a new revenue stream tied to compliance-heavy, high-margin cloud services.

SAP at a turning point? This analysis reveals what investors need to know now.

Sapphire Looms as a Catalyst

All eyes now turn to the SAP Sapphire conference in Orlando, where investor relations has scheduled an analyst session with board presentations and a Q&A. The company is expected to flesh out its AI strategy, potentially providing the kind of catalyst the stock has been lacking during a bruising first half.

Whether a fresh AI narrative can outweigh the weight of a 27% year-to-date drawdown remains the open question. But with the dividend paid, the healthcare bet announced, and a major conference on the horizon, the pieces are in place for a story that — if the market chooses to listen — could shift the conversation away from the share price’s recent misery.

Ad

SAP Stock: New Analysis - 8 May

Fresh SAP information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated SAP analysis...

en | DE0007164600 | SAP’S | boerse | 69294514 |